A naturally attenuated vaccine4
Since the reassortants in RotaTeq
are derived from a bovine rotavirus,
RotaTeq replicates poorly in humans, with a low rate
and short duration of viral shedding.4
In Phase 3 studies, shedding was observed as early
as 1 day and as late as 15 days after a dose. Transmission
was not evaluated in clinical trials.
Select safety information
Caution is advised
when considering whether to administer RotaTeq to individuals
with immunodeficient contacts. RotaTeq is a solution
of live reassortant rotaviruses and can potentially be
transmitted
to persons who have contact with the vaccine. The potential
risk of transmission of vaccine virus should be weighed
against the risk of acquiring and transmitting natural
rotavirus.
Before administering
RotaTeq, please read the Prescribing
Information and Patient
Product Information. RotaTeq is a registered trademark of Merck & Co., Inc.
|
